I probably take the alternative view and that is purely because...

I probably take the alternative view and that is purely because JP made reference to Reata and specifically noted that their value related to their ability to treat one condition.

I could be totally wrong, but I think JP and the board know this is worth much, much, much more because we can treat multiple and that is just scratching the surface. I don't think it would test the resolve of the company as much as it would test the resolve of a specific class of investor who are happy with a 100-200% return from here, rather than a potential 10-fold return in the medium term.